MDxHealth, Inc. To Participate In Canaccord Genuity Growth Conference
IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, August 2, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced that it will participate in the 37th Annual Canaccord Genuity Growth Conference to be held at the InterContinental Hotel in Boston, Massachusetts, US on August 9-10.
Dr. Jan Groen, CEO, MDxHealth will present at 13:30 EDT on Thursday, August 10. The company's CEO will discuss business and financial developments and trends. The presentation will be available on the Company's website after the conference.
About MDxHealth
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
For more information:
Jean-Marc Roelandt, Chief Financial Officer
MDxHealth
+32 (0) 4 364 20 70
IR@mdxhealth.com
Dr. Jan Groen, CEO, MDxHealth will present at 13:30 EDT on Thursday, August 10. The company's CEO will discuss business and financial developments and trends. The presentation will be available on the Company's website after the conference.
About MDxHealth
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
For more information:
Jean-Marc Roelandt, Chief Financial Officer
MDxHealth
+32 (0) 4 364 20 70
IR@mdxhealth.com